Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Clinical Trial
Official title:
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with B-cell Acute Lymphoblastic Leukemia that has come back (recurrent) or does not respond to treatment (refractory). T cells are infection fighting blood cells that can kill cancer cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize BAFFR, a protein on the surface of cancer cells. These BAFFR-specific T cells may help the body's immune system identify and kill BAFFR+ cancer cells. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05105867 -
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
|
Early Phase 1 | |
| Terminated |
NCT02588456 -
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT05054257 -
CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT02215629 -
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
|
Phase 1 |